Enzyme-selective effects of nitric oxide on affinity and maximum velocity of various rat cytochromes P450

Drug Metabolism and Disposition

Volumn 33, Issue 6, 2005, Pages 829-836

  Vuppugalla, Ragini ^a   Mehvar, Reza ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYCHLORZOXAZONE; BENZYLOXYRESORUFIN O DEALKYLASE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2C11; CYTOCHROME P450 2D1; CYTOCHROME P450 2E1; CYTOCHROME P450 3A2; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; ETHOXYRESORUFIN DEETHYLASE; ISOSORBIDE DINITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; UNCLASSIFIED DRUG; UNCLASSIFIED ENZYME;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEALKYLATION; DEMETHYLATION; DRUG EFFECT; DRUG MECHANISM; DRUG RELEASE; ENZYME ACTIVITY; ENZYME KINETICS; HYDROXYLATION; KINETICS; LIVER MICROSOME; LIVER PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ISOENZYMES; LIVER; MALE; NITRIC OXIDE; NITRIC OXIDE DONORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 18844451951     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.105.003848     Document Type: Article

References (39)

1. Bogaards JJP, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, vanBladeren PJ, and Walther B (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131-1152.
2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
3. Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T, and Mayer RT (1985) Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem Pharmacol 34:3337-3345.
4. Court MH, Von Moltke LL, Shader RI, and Greenblatt DJ (1997) Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 18:213-226.
5. Ekins S, Ring BJ, Binkley SN, Hall SD, and Wrighton SA (1998) Autoactivation and activation of the cytochrome P450s. Int J Clin Pharmacol Ther 36:642-651.
6. Ekins S, VandenBranden M, Ring BJ, and Wrighton SA (1997) Examination of purported probes of human CYP2B6. Pharmacogenetics 7:165-179.
7. Feelisch M (1998) The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch Pharmacol 358:113-122.
8. Gergel D, Misik V, Riesz P, and Cederbaum AI (1997) Inhibition of rat and human cytochrome P4502E1 catalytic activity and reactive oxygen radical formation by nitric oxide. Arch Biochem Biophys 337;239-250.
9. Ghezzi P, Saccardo B, Villa P, Rossi V, Bianchi M, and Dinarello CA (1986) Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infect Immun 54:837-840.
10. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
11. Howard LA, Micu AL, Sellers EM, and Tyndale RF (2001) Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. J Pharmacol Exp Ther 299:542-550.
12. Ioannidis I, Hellinger A, Dehmlow C, Rauen U, Erhard J, Eigler FW, and De Groot H (1995) Evidence for increased nitric oxide production after liver transplantation in humans. Transplantation 59:1293-1297.
13. Jayyosi Z, Knoble D, Muc M, Erick J, Thomas PE, and Kelley M (1995) Cytochrome P-450 2E1 is not the sole catalyst of chlorzoxazone hydroxylation in rat liver microsomes. J Pharmacol Exp Ther 273:1156-1161.
14. Kerry NL, Somogyi AA, Mikus G, and Bochner F (1993) Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes. Biochem Pharmacol 45:833-839.
15. Khatsenko O (1998) Interactions between nitric oxide and cytochrome P-450 in the liver. Biochemistry (Mosc) 63:833-839.
16. Khatsenko OG, Gross SS, Rifkind AB, and Vane JR (1993) Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proc Natl Acad Sci USA 90:11147-11151.
17. Khatsenko O and Kikkawa Y (1997) Nitric oxide differentially affects constitutive cytochrome P450 isoforms in rat liver. J Pharmacol Exp Ther 280:1463-1470.
18. Kim YM, Bergonia HA, Muller C, Pitt BR, Watkins WD, and Lancaster JR Jr (1995) Loss and degradation of enzyme-bound heme induced by cellular nitric oxide synthesis. J Biol Chem 270:5710-5713.
19. Li-Masters T and Morgan ET (2002) Down-regulation of phenobarbital- induced cytochrome P4502B mRNAs and proteins by endotoxin in mice: independence from nitric oxide production by inducible nitric oxide synthase. Biochem Pharmacol 64:1703-1711.
20. Mayer RT, Netter KJ, Heubel F, Hahnemann B, Buchheister A, Mayer GK, and Burke MD (1990) 7-Alkoxyquinolines: new fluorescent substrates for cytochrome P450 monooxygenases. Biochem Pharmacol 40:1645-1655.
21. Minamiyama Y, Takemura S, Imaoka S, Funae Y, Tanimoto Y, and Inoue M (1997) Irreversible inhibition of cytochrome P450 by nitric oxide. J Pharmacol Exp Ther 283:1479-1485.
22. Morgan ET (1997) Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29:1129-1188.
23. Morgan ET (2001) Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab Dispos 29:207-212.
24. Nathan C (1992) Nitric oxide as a secretory product of mammalian cells. FASEB J 6:3051-3064.
25. Paine MJI, McLaughlin LA, Flanagan JU, Kemp CA, Sutcliffe MJ, Roberts GCK, and Wolf CR (2003) Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem 278:4021-4027.
26. Purdon MP and Lehman-McKeeman LD (1997) Improved high-performance liquid chromatographic procedure for the separation and quantification of hydroxytestosterone metabolites. J Pharmacol Toxicol Methods 37:67-73.
27. Renton KW (2004) Cytochrome p450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 5:235-243.
28. Riddick DS, Lee C, Bhathena A, Timsit YE, Cheng P-Y, Morgan ET, Prough RA, Ripp SL, Miller KKM, Jahan A, et al. (2004) Transcriptional suppression of cytochrome P450 genes by endogenous and exogenous chemicals. Drug Metab Dispos 32:367-375.
29. Rutten AA, Falke HE, Catsburg JF, Wortelboer HM, Blaauboer BJ, Doorn L, van Leeuwen FX, Theelen R, and Rietjens IM (1992) Interlaboratory comparison of microsomal ethoxyresorufin and pentoxyresorufin O-dealkylation determinations: standardization of assay conditions. Arch Toxicol 66:237-244.
30. Schwab GE, Raucy JL, and Johnson EF (1988) Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Mol Pharmacol 33:493-499.
31. Sewer MB, Barclay TB, and Morgan ET (1998) Down-regulation of cytochrome P450 mRNAs and proteins in mice lacking a functional NOS2 gene. Mol Pharmacol 54:273-279.
32. Sewer MB and Morgan ET (1998) Down-regulation of the expression of three major rat liver cytochrome P450s by endotoxin in vivo occurs independently of nitric oxide production. J Pharmacol Exp Ther 287:352-358.
33. Stadler J, Trockfeld J, Schmalix WA, Brill T, Siewert JR, Greim H, and Doehmer J (1994) Inhibition of cytochromes P4501A by nitric oxide. Proc Natl Acad Sci USA 91:3559-3563.
34. Takemura S, Minamiyama Y, Imaoka S, Funae Y, Hirohashi K, Inoue M, and Kinoshita H (1999) Hepatic cytochrome P450 is directly inactivated by nitric oxide, not by inflammatory cytokines, in the early phase of endotoxemia. J Hepatol 30:1035-1044.
35. Vuppugalla R and Mehvar R (2004a) Hepatic disposition and effects of nitric oxide donors: rapid and concentration-dependent reduction in the cytochrome P450-mediated drug metabolism in isolated perfused rat livers. J Pharmacol Exp Ther 310:718-727.
36. Vuppugalla R and Mehvar R (2004b) Short-term inhibitory effects of nitric oxide on cytochrome P450-mediated drug metabolism: time dependency and reversibility profiles in isolated perfused rat livers. Drug Metab Dispos 32:1446-1454.
37. Warren GW, Poloyac SM, Gary DS, Mattson MP, and Blouin RA (1999) Hepatic cytochrome P-450 expression in tumor necrosis factor-alpha receptor (p55/p75) knockout mice after endotoxin administration. J Pharmacol Exp Ther 288:945-950.
38. Wink DA, Osawa Y, Darbyshire JF, Jones CR, Eshenaur SC, and Nims RW (1993) Inhibition of cytochromes P450 by nitric oxide and a nitric oxide-releasing agent. Arch Biochem Biophys 300:115-123.
39. Witherow LE and Houston JB (1999) Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J Pharmacol Exp Ther 290:58-65.